| dc.contributor.author | Fredrick Ogumbo, Ronald Odero, Ben Odhiambo, Patrick Emojong, Albert Okumu, James Nonoh, Steve Wandiga, Bernard Guya | |
| dc.date.accessioned | 2022-07-08T09:00:33Z | |
| dc.date.available | 2022-07-08T09:00:33Z | |
| dc.date.issued | 2022-03 | |
| dc.identifier.uri | https://repository.maseno.ac.ke/handle/123456789/5317 | |
| dc.description | https://doi.org/10.24248/easci.v4i1.57 | en_US |
| dc.description.abstract | Tuberculosis drug resistance is often associated with inadequate anti-tuberculosis treatment regimen resulting to mutations that confers resistance to anti-tuberculosis agents. This is aggravated by synergetic relationship between Tuberculosis and HIV (Human Immunodeficiency Virus). Over 25% of Global Tuberculosis deaths occur in Africa and Kenya is one of the 30 high burden countries that together account for more than 80% of the world’s TB cases. According to World Health Organization, in 2018, Multi drug resistant Tuberculosis prevalence in Kenya was 1.3% in new cases and 4.4% in retreatment cases. Kisumu County recorded the second highest HIV prevalence at 18.6% against the national prevalence of 4.5% in 2020. The extent of regional burden of DR-TB and HIV co-infection has not been exactly well-defined in Western Kenya. | en_US |
| dc.publisher | East Africa Science | en_US |
| dc.title | Isoniazid and Rifampicin Tuberculosis Drug Resistance in HIV Endemic Region of Western Kenya | en_US |
| dc.type | Article | en_US |
